Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.39
ITMN's Cash to Debt is ranked higher than
66% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. ITMN: 2.39 )
ITMN' s 10-Year Cash to Debt Range
Min: 0.65   Max: No Debt
Current: 2.39

Equity to Asset 0.53
ITMN's Equity to Asset is ranked higher than
64% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ITMN: 0.53 )
ITMN' s 10-Year Equity to Asset Range
Min: -0.92   Max: 0.98
Current: 0.53

-0.92
0.98
F-Score: 5
Z-Score: 12.63
M-Score: -1.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -188.88
ITMN's Operating margin (%) is ranked higher than
64% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. ITMN: -188.88 )
ITMN' s 10-Year Operating margin (%) Range
Min: -2967.17   Max: 48.26
Current: -188.88

-2967.17
48.26
Net-margin (%) -207.91
ITMN's Net-margin (%) is ranked higher than
64% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. ITMN: -207.91 )
ITMN' s 10-Year Net-margin (%) Range
Min: -2862.47   Max: 51.15
Current: -207.91

-2862.47
51.15
ROE (%) -68.13
ITMN's ROE (%) is ranked higher than
59% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. ITMN: -68.13 )
ITMN' s 10-Year ROE (%) Range
Min: -226.31   Max: 81.97
Current: -68.13

-226.31
81.97
ROA (%) -35.97
ITMN's ROA (%) is ranked higher than
65% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. ITMN: -35.97 )
ITMN' s 10-Year ROA (%) Range
Min: -106.78   Max: 40.1
Current: -35.97

-106.78
40.1
ROC (Joel Greenblatt) (%) -4287.17
ITMN's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. ITMN: -4287.17 )
ITMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6853.27   Max: 9266.21
Current: -4287.17

-6853.27
9266.21
Revenue Growth (%) -39.60
ITMN's Revenue Growth (%) is ranked higher than
60% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ITMN: -39.60 )
ITMN' s 10-Year Revenue Growth (%) Range
Min: -58.3   Max: 91.6
Current: -39.6

-58.3
91.6
» ITMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ITMN Guru Trades in Q3 2013

PRIMECAP Management 6,452,100 sh (+5.39%)
Columbia Wanger 2,770,000 sh (+2.9%)
Steven Cohen 447,700 sh (-77.38%)
» More
Q4 2013

ITMN Guru Trades in Q4 2013

PRIMECAP Management 6,472,100 sh (+0.31%)
Steven Cohen Sold Out
Columbia Wanger 2,612,000 sh (-5.7%)
» More
Q1 2014

ITMN Guru Trades in Q1 2014

Chuck Royce 328,000 sh (New)
Steven Cohen 7,637 sh (New)
PRIMECAP Management 6,627,500 sh (+2.4%)
Columbia Wanger 1,120,800 sh (-57.09%)
» More
Q2 2014

ITMN Guru Trades in Q2 2014

Jim Simons 426,129 sh (New)
Joel Greenblatt 6,487 sh (New)
Steven Cohen 240,600 sh (unchged)
Columbia Wanger Sold Out
Chuck Royce 278,000 sh (-15.24%)
PRIMECAP Management 4,525,925 sh (-31.71%)
» More
» Details

Insider Trades

Latest Guru Trades with ITMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 Reduce -31.71%0.08%$26.59 - $47.22 $ 73.72101%4525925
Joel Greenblatt 2014-06-30 New Buy$26.59 - $47.22 $ 73.72101%6487
PRIMECAP Management 2013-03-31 Add 77.69%0.03%$8.39 - $10.74 $ 73.72672%5643289
PRIMECAP Management 2012-03-31 Add 177.48%0.04%$12.35 - $16.64 $ 73.72436%2907700
PRIMECAP Management 2011-09-30 Add 31.54%0.01%$20.78 - $37.15 $ 73.72160%983900
PRIMECAP Management 2011-06-30 Add 53.28%0.01%$32.71 - $51.08 $ 73.7284%748000
George Soros 2011-06-30 Sold Out $32.71 - $51.08 $ 73.7284%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 21.40
ITMN's P/B is ranked higher than
60% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. ITMN: 21.40 )
ITMN' s 10-Year P/B Range
Min: 2.98   Max: 27.19
Current: 21.4

2.98
27.19
P/S 59.10
ITMN's P/S is ranked higher than
66% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. ITMN: 59.10 )
ITMN' s 10-Year P/S Range
Min: 2.19   Max: 110.21
Current: 59.1

2.19
110.21
EV-to-EBIT -34.30
ITMN's EV-to-EBIT is ranked higher than
59% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ITMN: -34.30 )
ITMN' s 10-Year EV-to-EBIT Range
Min: 7.4   Max: 26.3
Current: -34.3

7.4
26.3
Current Ratio 6.99
ITMN's Current Ratio is ranked higher than
83% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. ITMN: 6.99 )
ITMN' s 10-Year Current Ratio Range
Min: 1.08   Max: 52.48
Current: 6.99

1.08
52.48
Quick Ratio 6.87
ITMN's Quick Ratio is ranked higher than
84% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. ITMN: 6.87 )
ITMN' s 10-Year Quick Ratio Range
Min: 1.07   Max: 52.34
Current: 6.87

1.07
52.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.50
ITMN's Price/Net Cash is ranked higher than
80% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. ITMN: 28.50 )
ITMN' s 10-Year Price/Net Cash Range
Min: 2.96   Max: 195
Current: 28.5

2.96
195
Price/Net Current Asset Value 25.60
ITMN's Price/Net Current Asset Value is ranked higher than
78% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. ITMN: 25.60 )
ITMN' s 10-Year Price/Net Current Asset Value Range
Min: 2.91   Max: 142.62
Current: 25.6

2.91
142.62
Price/Tangible Book 22.50
ITMN's Price/Tangible Book is ranked higher than
65% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. ITMN: 22.50 )
ITMN' s 10-Year Price/Tangible Book Range
Min: 2.82   Max: 19.31
Current: 22.5

2.82
19.31
Price/Median PS Value 5.50
ITMN's Price/Median PS Value is ranked higher than
67% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. ITMN: 5.50 )
ITMN' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 23.74
Current: 5.5

0.24
23.74
Earnings Yield (Greenblatt) 1.20
ITMN's Earnings Yield (Greenblatt) is ranked higher than
57% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ITMN: 1.20 )
ITMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 13.5
Current: 1.2

1.2
13.5
Forward Rate of Return (Yacktman) -2.40
ITMN's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ITMN: -2.40 )
ITMN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.4   Max: -3.7
Current: -2.4

-15.4
-3.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IUX.Germany
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
» More Articles for ITMN

Headlines

Articles On GuruFocus.com
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly CEO Sells Highlight: Protective Life Corp, Western Refining Inc, InterMune Inc, and Tableau S Aug 18 2014 
Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN Mar 03 2014 
11 Mar 07 2012 
WEEKLY CFO SELLS HIGHLIGHT: ITMN, DISCA, WEC, EMAN, WTW, CAH May 22 2011 
InterMune Inc. (ITMN) Chairman, CEO and President Daniel G Welch sells 44,000 Shares Mar 04 2011 
InterMune Inc. Reports Operating Results (10-Q) Nov 08 2010 
InterMune Inc. Reports Operating Results (10-Q) Aug 09 2010 
InterMune Inc. (ITMN) SVP-Finance & CFO John Hodgman sells 11,436 Shares May 18 2010 

More From Other Websites
Roche's $8 billion InterMune buy not a signal for more big deals Sep 16 2014
[video] Cramer: ACAD and ISIS have room to run Sep 11 2014
INTERMUNE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 05 2014
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015 Sep 05 2014
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action... Sep 03 2014
Lifshitz & Miller Law Firm Announces Investigation of China Housing & Land Development, Inc., Cobra... Sep 02 2014
Investor Lawsuit Against Takeover of InterMune Inc (ITMN) Announced by Shareholders Foundation Sep 02 2014
What You Need to Know About the Roche-InterMune Deal Aug 29 2014
[$$] An $8.3 Billion Rebuke to the FDA Aug 29 2014
Cramer: Sector could be hotbed of 'bolt-on' deals Aug 28 2014
InterMune downgraded by UBS Aug 28 2014
InterMune drug may offer big upside to Roche if aimed at liver Aug 27 2014
InterMune Stockholders Encouraged to Contact Securities Law Firm about Takeover Aug 27 2014
INTERMUNE SHAREHOLDER ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the... Aug 27 2014
INTERMUNE INVESTOR ALERT: Faruqi & Faruqi, LLP is Investigating the Board of Directors of InterMune,... Aug 27 2014
Roche, InterMune a Strategic Play in Midst of Inversions Aug 27 2014
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology... Aug 27 2014
INVESTOR ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of... Aug 26 2014
Celgene, Gilead Lead Big Biotech Stock Movers Aug 26 2014
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally Aug 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK